Xiangguo Qiu 1 , Gary Wong 1 , 2 , Jonathan Audet 1 , 2 , Alexander Bello 1 , 2 , Lisa Fernando 1 , Judie B. Alimonti 1 , Hugues Fausther-Bovendo 1 , 2 , Haiyan Wei 1 , 3 , Jenna Aviles 1 , Ernie Hiatt 4 , Ashley Johnson 4 , Josh Morton 4 , Kelsi Swope 4 , Ognian Bohorov 5 , Natasha Bohorova 5 , Charles Goodman 5 , Do Kim 5 , Michael H. Pauly 5 , Jesus Velasco 5 , James Pettitt 6 , Gene G. Olinger 6 , Kevin Whaley 5 , Bianli Xu 3 , James E. Strong 1 , 2 , 7 , Larry Zeitlin 5 , Gary P. Kobinger 1 , 2 , 8 , 9
29 August 2014
Without an approved vaccine or treatment, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. Here we show that a combination of monoclonal antibodies (ZMapp ™), optimized from two previous antibody cocktails, is able to rescue 100% of rhesus macaques when treatment is initiated up to 5 days post-challenge. High fever, viremia, and abnormalities in blood count and chemistry were evident in many animals before ZMapp ™ intervention. Advanced disease, as indicated by elevated liver enzymes, mucosal hemorrhages and generalized petechia could be reversed, leading to full recovery. ELISA and neutralizing antibody assays indicate that ZMapp ™ is cross-reactive with the Guinean variant of Ebola. ZMapp ™ currently exceeds all previous descriptions of efficacy with other therapeutics, and results warrant further development of this cocktail for clinical use.